Reirradiation of head and neck cancer: Long-term disease control and toxicity.

Reirradiation of head and neck cancer: Long-term disease control and toxicity.

Head Neck. 2017 Mar 06;:

Authors: Bots WT, van den Bosch S, Zwijnenburg EM, Dijkema T, van den Broek GB, Weijs WL, Verhoef LC, Kaanders JH

Abstract
BACKGROUND: The purpose of this study was to report long-term disease control and late radiation toxicity for patients reirradiated for head and neck cancer.
METHODS: We conducted a retrospective analysis of 137 patients reirradiated with a prescribed dose ≥45 Gy between 1986 and 2013 for a recurrent or second primary malignancy. Endpoints were locoregional control, overall survival (OS), and grade ≥4 late complications according to European Organization for Research and Treatment of Cancer (EORTC)/Radiation Therapy Oncology Group (RTOG) criteria.
RESULTS: Five-year locoregional control rates were 46% for patients reirradiated postoperatively versus 20% for patients who underwent reirradiation as the primary treatment (p < .05). Sixteen cases of serious (grade ≥4) late toxicity were seen in 11 patients (actuarial 28% at 5 years). In patients reirradiated with intensity-modulated radiotherapy (IMRT), a borderline improved locoregional control was observed (49% vs 36%; p = .07), whereas late complication rates did not differ.
CONCLUSION: Reirradiation should be considered for patients with a recurrent or second primary head and neck cancer, especially postoperatively, if indicated. © 2017 The Authors Head & Neck Published by Wiley Periodicals, Inc. Head Neck, 2017.

PMID: 28263446 [PubMed - as supplied by publisher]

http://ift.tt/2mepZVi